Last reviewed · How we verify
Mimosin (mimosine)
Mimosin (generic name: mimosine) is a drug. It is currently in unknown development.
Mimosin works by inhibiting the enzyme tyrosinase, which is involved in the production of melanin from the amino acid tyrosine.
Mimosine is a toxic non-protein amino acid that occurs in some Mimosa species and all members of the related genus Leucaena, chemically similar to tyrosine. It is a small molecule.
At a glance
| Generic name | mimosine |
|---|---|
| Target | Deoxyhypusine hydroxylase, Serine hydroxymethyltransferase, cytosolic, Tyrosinase |
| Therapeutic area | Ophthalmology |
| Phase | unknown |
Mechanism of action
Think of melanin like a pigment that gives color to your skin, hair, and eyes. Tyrosinase is the enzyme that helps turn the amino acid tyrosine into melanin. Mimosin blocks this process, which could potentially affect how much melanin is produced in the body.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mimosin CI brief — competitive landscape report
- Mimosin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Mimosin
What is Mimosin?
How does Mimosin work?
What is the generic name of Mimosin?
What development phase is Mimosin in?
What does Mimosin target?
Related
- Target: All drugs targeting Deoxyhypusine hydroxylase, Serine hydroxymethyltransferase, cytosolic, Tyrosinase
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Ophthalmology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing